SCM Life Sciences, Advancing as a Global Cell Therapy Specialist Company... "Focusing on Innovative New Drug Development"

[Asia Economy Reporter Yoo Hyun-seok] SCM Life Sciences (hereinafter SCM Life Sciences), a bio company specializing in the development of stem cell therapies and immune cell therapies, which is pursuing a KOSDAQ listing, announced on the 18th that it will begin demand forecasting for institutional investors.

Lee Byung-geon, CEO of SCM Life Sciences, stated, "Through the KOSDAQ listing, we will strengthen our research and development competitiveness and focus on domestic and international clinical trials and innovative new drug development to achieve visible results in the treatment of intractable diseases." He emphasized, "In particular, by expanding the immune cell pipeline in addition to existing stem cells and securing cGMP manufacturing facilities in the United States, we will create new growth engines and leap forward as a global cell therapy specialist company."

SCM Life Sciences' main pipelines include stem cell therapies for chronic graft-versus-host disease (GVHD), acute pancreatitis, atopic dermatitis, and liver cirrhosis, as well as immune oncology drugs such as 'CMN-001' for metastatic renal cell carcinoma and 'CAR-CIK-CD19' for acute lymphoblastic leukemia.

The company’s strategy is to maximize corporate value and competitiveness based on strengths such as outstanding competitiveness of core proprietary technologies, growth potential of key pipelines, innovation in treatments for intractable diseases, domestic and international clinical know-how and global networks, and global-level production and quality management systems.

SCM Life Sciences possesses proprietary core technology called the 'Subfractionation Culturing Method,' which enables the separation and culturing of stem cells with high purity and homogeneity, allowing the manufacture of high-purity stem cell therapies. Existing stem cell therapies had limitations due to low purity and lack of disease-specific treatments, resulting in high treatment costs. SCM Life Sciences explained that by innovatively increasing stem cell purity through the Subfractionation Culturing Method and selecting cell lines suitable for disease-specific efficacy markers, it implements disease-customized stem cell therapies that maximize therapeutic efficacy while reducing treatment costs.

Additionally, SCM Life Sciences is expanding its pipeline by adding a 'Cell Sheet' platform for treating renal fibrosis and uterine wall fibrosis, and a '3D Spheroid' platform for treating burns and diabetic foot ulcers, while also conducting research and development on patch-type (adhesive) stem cell therapies.

SCM Life Sciences plans to raise up to approximately KRW 32.4 billion through this public offering. The total number of shares offered is 1.8 million, with a desired price range of KRW 15,500 to KRW 18,000 per share. Demand forecasting for institutional investors will be conducted on the 19th to finalize the offering price, followed by general subscription on the 24th and 25th.

The proceeds from the offering will be used for research and development, clinical trials, production facility construction, introduction of new technologies, and investment in overseas affiliates. The company plans to focus on clinical and overseas market expansion and secure new pipelines to create continuous growth engines. Additionally, it will build a new GMP facility in Songdo, Incheon. Together with the cGMP facility of CoImmune located in North Carolina, USA, this will serve as a forward base for full-scale global market expansion. The Songdo GMP facility targets the Asian market, while CoImmune’s cGMP facility targets the US and European markets.

SCM Life Sciences is pursuing a KOSDAQ listing through a technology special listing. The lead underwriter is Korea Investment & Securities. The scheduled listing date is the 2nd of next month, and the expected market capitalization after listing is approximately KRW 182 billion to 211.3 billion based on the desired offering price.

This content was produced with the assistance of AI translation services.